{"id":"sm-13496-lurasidone-hcl","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Orthostatic hypotension"},{"rate":"10-20%","effect":"Weight gain"},{"rate":"10-20%","effect":"Somnolence"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lurasidone's mechanism of action involves blocking the action of serotonin and dopamine in the brain, which helps to reduce symptoms of psychosis and improve mood. This is achieved through its antagonism of the serotonin 2A receptor and the dopamine D2 receptor. By modulating these receptors, lurasidone helps to restore balance to the brain's neurotransmitter systems.","oneSentence":"SM-13496 (lurasidone HCl) is an atypical antipsychotic that acts as a serotonin 2A receptor antagonist and a dopamine receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:18.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06328140","phase":"","title":"Sleep Quality, Cognitive Performance, and Computerized Cognitive Training","status":"WITHDRAWN","sponsor":"George West Mental Health Foundation d/b/a Skyland Trail","startDate":"2024-04-15","conditions":"Bipolar Disorder, Major Depressive Disorder, Psychosis","enrollment":""},{"nctId":"NCT01569659","phase":"PHASE4","title":"High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2011-10","conditions":"Schizophrenia","enrollment":101},{"nctId":"NCT02731612","phase":"PHASE3","title":"Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients","status":"COMPLETED","sponsor":"Lakshmi N Yatham","startDate":"2017-05-08","conditions":"Bipolar Disorder","enrollment":100},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06527885","phase":"","title":"Lurasidone Non-Interventional Study in Schizophrenia Patients","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2022-10-21","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT03395392","phase":"PHASE2, PHASE3","title":"NRX-101 for Bipolar Depression With Subacute Suicidal Ideation","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2022-05-12","conditions":"Bipolar Depression, Suicidal Ideation and Behavior","enrollment":74},{"nctId":"NCT05213143","phase":"PHASE4","title":"The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine","status":"TERMINATED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2021-12-30","conditions":"Schizophrenia","enrollment":13},{"nctId":"NCT05011669","phase":"PHASE4","title":"The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2021-08-16","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT04432688","phase":"","title":"The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2020-12-01","conditions":"Schizophrenia","enrollment":3192},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03396068","phase":"PHASE3","title":"NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation","status":"UNKNOWN","sponsor":"NeuroRx, Inc.","startDate":"2019-12-01","conditions":"Bipolar Depression, Suicidal Ideation","enrollment":72},{"nctId":"NCT06128213","phase":"PHASE2","title":"NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis","status":"UNKNOWN","sponsor":"NeuroRx, Inc.","startDate":"2024-03-31","conditions":"Urinary Tract Infections, Pyelonephritis","enrollment":13},{"nctId":"NCT03902613","phase":"PHASE4","title":"18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-02-07","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05351736","phase":"PHASE4","title":"Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-01-26","conditions":"Schizophrenia","enrollment":10},{"nctId":"NCT03465787","phase":"PHASE3","title":"A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2018-04-09","conditions":"Schizophrenia","enrollment":210},{"nctId":"NCT04383691","phase":"PHASE3","title":"A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression","status":"TERMINATED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2020-12-11","conditions":"Bipolar I Depression","enrollment":124},{"nctId":"NCT05480150","phase":"NA","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-01","conditions":"Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic","enrollment":10000},{"nctId":"NCT03402152","phase":"PHASE2, PHASE3","title":"NRX101 Glx Biomarker Validation Study","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-11-01","conditions":"Bipolar Depression, Suicidal Ideation","enrollment":8},{"nctId":"NCT01614899","phase":"PHASE3","title":"A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2012-07-02","conditions":"Schizophrenia","enrollment":457},{"nctId":"NCT00711269","phase":"PHASE3","title":"Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2008-06-27","conditions":"Schizophrenia","enrollment":460},{"nctId":"NCT01614912","phase":"PHASE3","title":"Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":284},{"nctId":"NCT01986101","phase":"PHASE3","title":"A Phase III Study of SM-13496 in Patients With Bipolar I Depression.","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2014-02-19","conditions":"Bipolar Depression","enrollment":525},{"nctId":"NCT01986114","phase":"PHASE3","title":"A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2014-01-29","conditions":"Bipolar I Disorder","enrollment":495},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02974010","phase":"PHASE2","title":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-01-15","conditions":"Bipolar Depression, Suicidal Ideas, Suicidal Ideation","enrollment":22},{"nctId":"NCT02199743","phase":"PHASE4","title":"Lurasidone Effects on Tissue Glutamate in Schizophrenia","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":35},{"nctId":"NCT03627195","phase":"PHASE1","title":"A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-06-07","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT03304457","phase":"PHASE4","title":"Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-08-25","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT03393026","phase":"PHASE4","title":"A Study of Lurasidone HCl in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Standard Chem. & Pharm. Co., Ltd.","startDate":"2018-01-03","conditions":"Schizophrenia","enrollment":54},{"nctId":"NCT01914393","phase":"PHASE3","title":"Pediatric Open-Label Extension Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-09-30","conditions":"Schizophrenia, Autism, Bipolar Depression","enrollment":702},{"nctId":"NCT02002832","phase":"PHASE3","title":"A Clinical Trial of Lurasidone in Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2013-12","conditions":"Schizophrenia","enrollment":388},{"nctId":"NCT01566162","phase":"PHASE3","title":"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-04","conditions":"Schizophrenia","enrollment":191},{"nctId":"NCT02174523","phase":"PHASE1","title":"Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":14},{"nctId":"NCT02174510","phase":"PHASE1","title":"A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2014-03","conditions":"Schizophrenia","enrollment":37},{"nctId":"NCT01932541","phase":"PHASE4","title":"Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Mania, Bipolar I, Bipolar II","enrollment":""},{"nctId":"NCT02046369","phase":"PHASE3","title":"Lurasidone Pediatric Bipolar Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-03","conditions":"Bipolar I Depression","enrollment":350},{"nctId":"NCT02239094","phase":"NA","title":"Biosignatures of Latuda for Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2015-01","conditions":"Bipolar Depression","enrollment":20},{"nctId":"NCT01731119","phase":"PHASE2","title":"Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":9},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT01911429","phase":"PHASE3","title":"Pediatric Schizophrenia Efficacy and Safety Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-08","conditions":"Schizophrenia","enrollment":327},{"nctId":"NCT02147379","phase":"PHASE3","title":"Lurasidone and Cognition in Bipolar I Disorder","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2014-05","conditions":"Bipolar I Disorder","enrollment":53},{"nctId":"NCT01485640","phase":"PHASE3","title":"Lurasidone Extended Use Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Schizophrenia, Bipolar Disorder","enrollment":162},{"nctId":"NCT01358357","phase":"PHASE3","title":"Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Bipolar I Disorder","enrollment":965},{"nctId":"NCT01575561","phase":"PHASE3","title":"This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-06","conditions":"Bipolar I Disorder","enrollment":377},{"nctId":"NCT01821378","phase":"PHASE3","title":"Lurasidone Low-Dose - High-Dose Study Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-05","conditions":"Schizophrenia","enrollment":412},{"nctId":"NCT01421134","phase":"PHASE3","title":"Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-09","conditions":"Major Depressive Disorder With Mixed Features","enrollment":211},{"nctId":"NCT01833897","phase":"PHASE4","title":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-03","conditions":"Bipolar Disorder","enrollment":8},{"nctId":"NCT00868959","phase":"PHASE3","title":"Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":817},{"nctId":"NCT01620060","phase":"PHASE1","title":"Lurasidone Pediatric Pharmacokinetics Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-06","conditions":"Schizophrenia, Autism","enrollment":105},{"nctId":"NCT01423253","phase":"PHASE3","title":"Major Depressive Disorder With Mixed Features - Extension","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":48},{"nctId":"NCT01435928","phase":"PHASE3","title":"PEARL Schizophrenia Maintenance","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-09","conditions":"Schizophrenia","enrollment":676},{"nctId":"NCT00088634","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-05","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT00790192","phase":"PHASE3","title":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia","enrollment":488},{"nctId":"NCT01911442","phase":"PHASE3","title":"Lurasidone Pediatric Autism Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-08","conditions":"Autism","enrollment":150},{"nctId":"NCT00641745","phase":"PHASE3","title":"Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":629},{"nctId":"NCT00789698","phase":"PHASE3","title":"Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Chronic Schizophrenia","enrollment":240},{"nctId":"NCT01143090","phase":"PHASE3","title":"A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":149},{"nctId":"NCT00615433","phase":"PHASE3","title":"Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":478},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00549718","phase":"PHASE3","title":"Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-10","conditions":"Schizophrenia","enrollment":489},{"nctId":"NCT00044044","phase":"PHASE2","title":"A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-07","conditions":"Schizophrenia","enrollment":356},{"nctId":"NCT00868452","phase":"PHASE3","title":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":348},{"nctId":"NCT00088621","phase":"PHASE2","title":"A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT00044005","phase":"PHASE2","title":"Safety and Tolerability Study of Drug to Treat Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-09","conditions":"Schizophrenia","enrollment":98},{"nctId":"NCT00868699","phase":"PHASE3","title":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":505},{"nctId":"NCT01082146","phase":"PHASE1","title":"RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Pharmacokinetics, Metabolism","enrollment":6},{"nctId":"NCT01284517","phase":"PHASE3","title":"Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-11","conditions":"Bipolar Depression","enrollment":356},{"nctId":"NCT01979679","phase":"PHASE3","title":"A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2008-12","conditions":"Schizophrenia","enrollment":28},{"nctId":"NCT01143077","phase":"PHASE3","title":"A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":244},{"nctId":"NCT01423240","phase":"PHASE3","title":"Major Depressive Disorder With Mixed Features","status":"WITHDRAWN","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT00549666","phase":"PHASE1","title":"A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-08","conditions":"Pharmacokinetics","enrollment":23},{"nctId":"NCT01074632","phase":"PHASE1","title":"Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-05","conditions":"Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder","enrollment":26},{"nctId":"NCT01074073","phase":"PHASE1","title":"Lithium Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT01082263","phase":"PHASE1","title":"Midazolam Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia Patients","enrollment":24},{"nctId":"NCT01082289","phase":"PHASE1","title":"Digoxin Drug-Drug Interaction With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT01082276","phase":"PHASE1","title":"Rifampin Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Male, Healthy Normal Subjects","enrollment":20},{"nctId":"NCT01082250","phase":"PHASE1","title":"The Bioequivalence Of Two Different Lurasidone Formulations In Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SM-13496 (lurasidone HCl)","genericName":"SM-13496 (lurasidone HCl)","companyName":"Sumitomo Pharma Co., Ltd.","companyId":"sumitomo-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SM-13496 (lurasidone HCl) is an atypical antipsychotic that acts as a serotonin 2A receptor antagonist and a dopamine receptor antagonist. Used for Schizophrenia, Bipolar I disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}